Biotechnology - Zalicus

Filter

Current filters:

Zalicus

Popular Filters

Zalicus slumps as pain drug Z160 fails in Ph II

11-11-2013

US biotech firm Zalicus saw its shares plunge 71.5% in early trading, after the company revealed announced…

BiotechnologyNeurologicalResearchZ944Zalicus

Zalicus drops Synavive RA drug after disappointing Ph IIb results

12-09-2012

US biotech firm Zalicus (Nasdaq: ZLCS) saw its shares plunge nearly 40% to $0.84 in afternoon trading…

Anti-Arthritics/RheumaticsBiotechnologyResearchSynaviveZalicus

Company Spotlight

ImmunoGen

ImmunoGen

Back to top